Rechercher des projets européens

Plus de 40 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

European Human Biomonitoring Initiative (HBM4EU)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,

The overarching goal of the European Human Biomonitoring Initiative (HBM4EU) is to generate knowledge to inform the safe management of chemicals and so protect human health. We will use human biomonitoring to understand human exposure to chemicals and resulting health impacts and will communicate with policy makers to ensure that our results are exploited in the design of new chemicals policies an ...
Voir le projet

 43

 TERMINÉ 

Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections (COMBACTE-MAGNET)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2021,

Antimicrobial resistance (AMR) is a major global public health threat, and most troublesome is the rapid emergence and dissemination of multidrug resistant (MDR) Enterobacteriaceae, Acinetobacter species and Pseudomonas aeruginosa. There is an unmet medical need to prevent P. aeruginosa infection in critically ill patients and to develop new antibiotics for infections caused by Gram-negative bacte ...
Voir le projet

 44

 TERMINÉ 

REgenerative Stem cell therapy for STroke in Europe (RESSTORE)

Date du début: 1 sept. 2015, Date de fin: 31 août 2020,

Stroke is the second leading cause of death in the world population. When not fatal, stroke often results in disability, due to motor and cognitive impairments, and secondary health problems affecting not only patients but also their families. Building on emerging preclinical and pilot clinical evidences, RESSTORE will focus on the clinical assessment of regenerative cell therapy to improve stroke ...
Voir le projet

 29

 TERMINÉ 

Application of omics-based strategies for improved diagnosis and treatment of endocrine hypertension (ENSAT-HT)

Date du début: 1 mai 2015, Date de fin: 30 avr. 2020,

Arterial hypertension affects up to 45% of the general population and is responsible for 7.1 million deaths per year worldwide. Although a large therapeutic arsenal exists, blood pressure control is sub-optimal in up to two thirds of patients. Yet, even small increments in blood pressure are associated with increased cardiovascular risk, with 62% of cerebrovascular disease and 49% of ischemic hear ...
Voir le projet

 13

 TERMINÉ 

Imaging the Force of Cancer (FORCE)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,

Cancer is the second leading cause of mortality in EU member states with ~90% of all cancer deaths caused by metastatic spread. Despite its significance, measuring metastatic potential as well as potential indicators of therapy efficacy remain unmet clinical challenges. Recently, it has been demonstrated in vitro, that aggressive metastatic cells pull on their surroundings suggesting that metastat ...
Voir le projet

 18

 TERMINÉ 

European Prevention of Alzheimer’s Dementia Consortium (EPAD)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2019,

Background:The secondary prevention of Alzheimer’s dementia (AD) is achievable if we can identify individuals at risk of disease progression defined by biomarker evidence of AD pathology and no or only minimal clinical symptoms and engage them in a standing adaptive clinical trial, of the highest quality, testing multiple interventions. To achieve this, EPAD will also provide the analytical infras ...
Voir le projet

 40

 TERMINÉ 

Decision Support and Information Management System for Breast Cancer (DESIREE)

Date du début: 1 févr. 2016, Date de fin: 31 janv. 2019,

Breast cancer is the most common type of cancer affecting woman in the EU. Multidisciplinary Breast Units (BUs) were introduced in order to deal efficiently with breast cancer cases, setting guideline-based quality procedures and a high standard of care. However, daily practice in the BUs is hampered by the complexity of the disease, the vast amount of patient and disease data available in the dig ...
Voir le projet

 11

 TERMINÉ 

Clinical trial of autologous adipose-derived mesenchymal stromal cells (ASC) in the treatment of mild to moderate osteoarthritis (ADIPOA2)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2018,

Osteoarthritis (OA) is an incurable disease that has evaded pharmacological interference, biologic therapy or surgical intervention to prevent disease progression. Currently, OA is designated the 11th highest contributor (of 291 diseases) of global disability. In the absence of effective treatment options, cellular therapies using mesenchymal stem/stromal cells (MSCs) have emerged as potential can ...
Voir le projet

 20

 TERMINÉ 

TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development (TBVAC2020)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2018,

The TBVAC2020 proposal builds on the highly successful and long-standing collaborations in subsequent EC-FP5-, FP6- and FP7-funded TB vaccine and biomarker projects, but also brings in a large number of new key partners from excellent laboratories from Europe, USA, Asia, Africa and Australia, many of which are global leaders in the TB field. This was initiated by launching an open call for Express ...
Voir le projet

 49

 TERMINÉ 

I-MOVE+ Integrated Monitoring of Vaccines Effects in Europe: a platform to measure and compare effectiveness and impact of influenza and pneumococcal vaccines and vaccination strategies in the elderly (I-MOVE-plus)

Date du début: 1 mai 2015, Date de fin: 31 oct. 2018,

The I-MOVE+ Consortium includes European Union (EU) Public Health Institutes, SME and Universities. It aims at measuring and comparing the effectiveness (VE) and impact (VI) of influenza and Pneumococcal vaccines and vaccination strategies a in the elderly population in Europe. The goal is to develop a sustainable platform of primary care practices, hospitals and laboratory networks that share val ...
Voir le projet

 33

 TERMINÉ 

Metagenomics in Cardiometabolic Diseases (METACARDIS)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2018,

METACARDIS applies a systems medicine multilevel approach to identify biological relationships between gut microbiota, assessed by metagenomics, and host genome expression regulation, which will improve understanding and innovative care of cardiometabolic diseases (CMD) and their comorbidities. CMD comprise metabolic (obesity, diabetes) and heart diseases characterized by a chronic evolution in ag ...
Voir le projet

 18

 TERMINÉ 

Accelerated Development of Vaccine benefit-risk Collaboration in Europe (ADVANCE)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,

Aim: The ADVANCE vision is focused on Timely and Best Evidence on Vaccine Effects. Our mission is to establish a best practice framework to rapidly provide robust data on vaccine benefits and risks to support accelerated decision-making.Approach: To achieve this vision through a public-private partnership, ADVANCE partners 1. establish common grounds and rules for collaboration between public and ...
Voir le projet

 30

 TERMINÉ 

Biomarkers of renal graft injuries in kidney allograft recipients (BIOMARGIN)

Date du début: 1 mars 2013, Date de fin: 28 févr. 2018,

In renal allograft recipients, 10-year graft survival has not improved over the past decades. Histological examination of graft biopsies has long been the gold standard to confirm graft injuries, but biopsies are invasive and histological grading is not very robust. There is thus a need for robust, non-invasive methods to predict and diagnose acute and chronic graft lesions, to improve patient tre ...
Voir le projet

 13

 TERMINÉ 

Nanomedicine for target-specific imaging and treatment of atherosclerosis: development and initial clinical feasibility (NanoAthero)

Date du début: 1 févr. 2013, Date de fin: 31 janv. 2018,

NanoAthero aims to have demonstration of initial clinical feasibility of nanosystems for targeted imaging and treatment of advanced atherosclerotic disease in humans. The nanosystems are assemblies of following components: nanocarrier, targeting, imaging agent/drug. They have proven safety records, and strong preliminary in vitro and in vivo proofs of efficacy are available. Partners have patented ...
Voir le projet

 17

 TERMINÉ 

Progressing towards the construction of METROFOOD-RI (PRO-METROFOOD)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2017,

...s, relevant authorities supporting METROFOOD-RI and other stakeholders. A management conceptual model will be developed and the framework will be designed under operational, strategic and institutional aspects. Management procedures suitable for the different phases will set up, so to cover short and long-term goals. A Quality Documentation System (QDS) will be developed and a data management plan ...
Voir le projet

 17

 TERMINÉ 

European Medical Information Framework (EMIF)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,

In response to the need to tackle increasingly complex medical research questions, a growing amount of human health data is being collected, either in routine Electronic Healthcare Record (EHR) databases, through research-driven cohort studies, in biobanks or related efforts. However, data sources are typically fragmented and contain information gaps which prevent their full exploitation. EMIF aim ...
Voir le projet

 64

 TERMINÉ 

Phase I/II ex vivo gene therapy clinical trial for recessive dystrophic epidermolysis bullosa using skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector (GENEGRAFT)

Date du début: 1 mars 2011, Date de fin: 31 déc. 2017,

RDEB is one of the most severe rare genetic skin diseases of children and adults characterized by skin blistering resulting from lack of expression of type VII collagen. There is no treatment for this life-threatening disease. In March 2009, we obtained the orphan drug designation for the Medicinal product: “Skin equivalent graft genetically corrected with a COL7A1-encoding SIN retroviral vecto ...
Voir le projet

 10

 TERMINÉ 

Human pluripotent stem cell differentiation, safety and preparation for therapeutic transplantation in Huntington’s disease (Repair-HD)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,

This project will tackle the huge complexity of taking stem cell therapies to clinical application for neurodegenerative disease by focusing on selective differentiation of a single neuronal phenotype (medium spiny striatal neuron: MSN) for a single well-defined disease (Huntington’s: HD). Our consortium contains expertise in all elements required to drive this technology to the point of clinical ...
Voir le projet

 10

 TERMINÉ 

European Consortium for High-Throughput Research in Rare Kidney Diseases (EURENOMICS)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,

EURenOmics will integrate several established consortia devoted to rare kidney diseases with eminent need and potential for diagnostic and therapeutic progress (i.e. steroid resistant nephrotic syndrome, membranous nephropathy, tubulopathies, complement disorders such a haemolytic uraemic syndrome, and congenital kidney malformations). The Consortium has access to the largest clinical cohorts asse ...
Voir le projet

 29

 TERMINÉ 

Open Project for the European Radiation Research Area (OPERRA)

Date du début: 1 juin 2013, Date de fin: 31 mai 2017,

"Within the OPERRA project, it is proposed that the MELODI Association, as a well-advanced network, takes the lead in establishing the necessary structures able to manage the long-term European research programmes in radiation protection, also taking advantage of the valuable experience gathered through the DoReMi network of excellence. Whilst in fields adjacent to low-dose risk research (radioeco ...
Voir le projet

 71

 TERMINÉ 

Anti-Biopharmaceutical Immunization:Prediction and analysis of clinical relevance to minimize the risk (ABIRISK)

Date du début: 1 mars 2012, Date de fin: 28 févr. 2017,

The ABIRISK project provides an integrated approach to the study of immunization against biopharmaceuticals, bringing together a unique panel of experts from different disciplines. ABIRISK will involve many of the European leaders in rheumatology, gastroenterology, hemophilia and multiple sclerosis, caring for ~30,000 patients treated with biopharmaceuticals, with ~10,000 additional patients recru ...
Voir le projet

 39

 TERMINÉ 

NEURAL TRANSPLANTATION IN THE TREATMENT OF PATIENTS WITH PARKINSON’S DISEASE (TRANSEURO)

Date du début: 1 janv. 2010, Date de fin: 30 juin 2016,

There are currently no cures for Parkinson's disease (PD) but one of the most effective reparative therapies in patients to date has been with allotransplants of dopamine (DA) neuroblasts obtained from fetal ventral mesencephalic (VM) tissue. However, this cell transplantation approach has given inconsistent results, with some patients doing extremely well and coming off anti-PD medication for yea ...
Voir le projet

 15

 TERMINÉ 

Syndromic approach to Neglected Infectious Diseases (NID) at primary health care level: an international collaboration on integrated diagnostic-treatment platforms (NIDIAG)

Date du début: 1 nov. 2010, Date de fin: 30 avr. 2016,

Neglected Infectious Diseases (NID) such as trypanosomiasis, leishmaniasis, schistosomiasis and soil-transmitted helminthiasis receive less than 5% of the global investment for tropical diseases research. Clinical praxis in disease-endemic countries (DEC) is rarely evidence based and does not make use of the latest innovations in diagnostic technology. NID–related research on diagnostics is partic ...
Voir le projet

 13

 TERMINÉ 

Electronic Health Record systems for Clinical Research (EHR4CR)

Date du début: 1 mars 2011, Date de fin: 29 févr. 2016,

Current medical needs, the growth of targeted therapies and personalized medicines, and escalating R&D costs result in formidable cost pressures on healthcare systems and the pharmaceutical industry. Clinical research is also growing in complexity, labour intensity and cost. There is a growing realization that the development and integration of Electronic Health Record systems (EHRs) for medical ...
Voir le projet

 37

 TERMINÉ 

Treat Infections in NeoNates 2 - Evaluation of an infective agent (azithromycin) for the treatment of infections in preterm and term neonates (TINN2)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2015,

"The aim of TINN2 is to evaluate azithromycin, included in the EMEA priority list of the therapeutic areas that need specific drug evaluation in preterm and term neonates. Azithromycin is a macrolid antibiotic with anti-inflammatory properties active against Ureaplasma. It might be effective in reducing the severity of bronhopulmonary disease in which Ureaplasma infection and inflammation play a r ...
Voir le projet

 17

 TERMINÉ 

Evaluation of antibiotics (ciprofloxacin and fluconazole) for the treatment of infections in preterm and term neonates (TINN)

Date du début: 1 nov. 2008, Date de fin: 31 oct. 2015,

The aim of TINN is to evaluate ciprofloxacin, fluconazole and micafungin in neonates; two anti-infectious drugs included in the EMEA priority list of the therapeutic areas that need specific drug evaluation in preterm and term neonates. These drugs are prescribed off-label to treat neonatal infections that are life threatening situations and associated with long-term complications. In order to val ...
Voir le projet

 16

 TERMINÉ 

Regenerating Bone defects using New biomedical Engineering approaches (REBORNE)

Date du début: 1 janv. 2010, Date de fin: 30 juin 2015,

Bone is among the most frequently transplanted tissue with about 1 million procedures annually in Europe. The worldwide market of bone replacement materials is currently estimated at 5 billion € with a 10% annual growth. Despite their considerable disadvantages, including the risk of disease transfer and immunologic rejection, limited supply of bone, costs and complications, allografts and autogra ...
Voir le projet

 24

 TERMINÉ 

Suicidality: Treatment Occurring in Paediatrics (STOP)

Date du début: 1 nov. 2010, Date de fin: 30 avr. 2015,

The emergence of suicidality in patients receiving drug treatment is of concern because of the overall burden and the possible link with completed suicide. The lack of uniform requirements for defining, detecting and recording suicidality and the presence of disease related confounders create major problems. It is possible that Medication-Related Suicidality (MRS) differs from Psychopathology-Rela ...
Voir le projet

 19

 TERMINÉ 

Paediatric European Risperidone Studies (PERS)

Date du début: 1 mai 2010, Date de fin: 30 avr. 2015,

"Second-generation antipsychotics are increasingly being prescribed to children and adolescents. Their use, however, is mostly off-label, and adequate and sufficient data about efficacy and particular safety are lacking. This proposal focuses on two indications, the use of risperidone in children and adolescents with conduct disorder who are not mentally retarded, and the use of risperidone in ado ...
Voir le projet

 22

 TERMINÉ 

EU and North African Migrants: Health and Health Systems (EUNAM)

Date du début: 1 avr. 2011, Date de fin: 31 mars 2015,

The coordinates of human health are complex even in a single population but they are even more complex in migrants whose life situation is always influenced by the host country and the country of origin. Some migrants may experience several host countries and some return to the country of origin. Thus it is important to survey well being, health status, disease panorama and use of health services ...
Voir le projet

 8

 TERMINÉ 

Treatment of NEonatal seizures with Medication Off-patent: evaluation of efficacy and safety of bumetanide (NEMO)

Date du début: 1 oct. 2009, Date de fin: 31 mars 2015,

Neonatal hypoxic ischaemic encephalopathy (HIE) occurs in 2-3/1000 live births and is a major cause of both acute mortality and long-term neurodisability. Seizures are the hallmark of HIE. The clinical and electrographic seizure burden in babies with HIE can be considerable and is often not reduced by current antiepileptic drugs. Phenobarbitone remains the first line drug for neonatal seizures des ...
Voir le projet

 15

 TERMINÉ 

NCDs and their social determinants in Mediterranean partner countries: building sustainable research capacity for effective policy intervention (RESCAP-MED)

Date du début: 1 janv. 2012, Date de fin: 31 déc. 2014,

...nterventions. We prioritise five disciplines in this action: epidemiology, health economics, environmental health, medical anthropology, and health policy evaluation. These actions would create new institutional possibilities for the future, and are made more achievable because this proposal develops out of an existing FP7-funded research collaboration (MedCHAMPS, Grant number 223075) in several ...
Voir le projet

 12

 TERMINÉ 

Pan-European network for the study and clinical management of drug resistant tuberculosis (TB PAN-NET)

Date du début: 1 janv. 2009, Date de fin: 30 juin 2014,

"This proposal will establish an integrated and synergistic network to address the challenge of multiple drug resistant tuberculosis (MDR-TB) facing the EU. The objective will be attained through the establishment of a European consortium of expert partners with extensive experience in the conduct of basic and clinical research relating to MDR-TB, TB control and epidemiology. This Consortium will ...
Voir le projet

 32

 TERMINÉ 

EUROPEAN PHYTOSANITARY RESEARCH COORDINATION II (EUPHRESCO)

Date du début: 1 janv. 2011, Date de fin: 31 mars 2014,

The Community Plant Health Regime (CPHR) aims to prevent the introduction, establishment and spread of regulated and quarantine plant pests. These pests pose increasing risks to European agriculture, horticulture, forestry and the environment. This is due to increased globalisation of trade (volume and diversity), but is exacerbated by climate change and EU expansion (increased pathways). In compa ...
Voir le projet

 37

 TERMINÉ 

Discovery and preclinical development of new generation tuberculosis vaccines (NEWTBVAC)

Date du début: 1 janv. 2010, Date de fin: 28 févr. 2014,

"With 14.4 million prevalent cases and 1.7 million deaths tuberculosis (TB) remains one of the most serious infectious diseases to date. An estimated 2 billion people are believed to be infected with Mycobacterium tuberculosis and at risk of developing disease. Multi- and extensively drug resistant strains are increasingly appearing in many parts of the world, including Europe. While with current ...
Voir le projet

 39

 TERMINÉ 

Treatment of reperfusion injury using a mitochondrial targeted approach: towards a better understanding of the disease (MITOCARE)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2013,

"Current interventional treatment of acute myocardial infarction (AMI) focused on re-establishing cardiac reperfusion has significantly improved clinical outcome by reducing infarct size and mortality due to cardiac ischemia.It is now recognized that events triggered at reperfusion also result in cell death and may account for as much as 50% of the infarct volume, this being termed ischemia-reperf ...
Voir le projet

 18

 TERMINÉ 

Identification and development of vaccine candidates for Buruli Ulcer Disease (BuruliVac)

Date du début: 1 mars 2010, Date de fin: 31 mai 2013,

Buruli ulcer disease (BUD), caused by Mycobacterium ulcerans, is a neglected bacterial infection of the poor in remote rural areas, mostly affecting children. BUD, the third most common mycobacterial disease in immunocompetent humans after tuberculosis and leprosy, is most endemic in West Africa, but cases have been reported from more than 30 countries. BUD is a mutilating disease leading to sever ...
Voir le projet

 16

 TERMINÉ 

Europe against Cancer: Optimisation of the Use of Registries for Scientific Excellence in research (EUROCOURSE)

Date du début: 1 avr. 2009, Date de fin: 30 sept. 2012,

"EUROCOURSE will tackle fragmentation in the funding and usage of cancer registries in Europe. It will do so by exploring ways to link and integrate national/regional programmes aimed at supporting cancer registries and research carried out using registry data. At the same time EUROCOURSE is seeking to optimize the use of cancer registration data for the amelioration of cancer control and the stre ...
Voir le projet

 15

 TERMINÉ 

Paediatric European Network Treatment AIDS Laboratory Network (PENTA LABNET) (PENTA-LABNET)

Date du début: 1 mai 2008, Date de fin: 31 juil. 2012,

"PENTA-LABNET(PL) is a coordination action aimed at improving the range of products and clinical use of antiretrovirals(ARVs) in HIV-infected children in resource-rich and resource-limited countries. This will be achieved through building capacity of laboratories to undertake co-ordinated studies on pharmacokinetics, pharmacodynamics and pharmacogenetics of new formulations and dosing and studies ...
Voir le projet

 12

 TERMINÉ 

Guard, Anticipation and Prediction. A new approach to Health Risk Prediction (GAP)

Date du début: 1 janv. 2008, Date de fin: 31 déc. 2008,

The project GAP focuses on the area of « Patient safety and risk assessment » of the challenge 5 of FP7-ICT. It addresses, via specific workshops and studies, all aspects of risk prediction, evaluation of risk factors, evaluation and management tools designed for the preparation of means that allows an intervention in real situations. The project will evaluate insofar as possible all current sol ...
Voir le projet

 10